THE LOCALIZATION of animal and human tumours in vivo has been demonstrated by the use of radiolabelled affinitypurified conventional antibodies (Primus et al., 1973; Mach et al., 1974 Mach et al., , 1980 Goldenberg et al., 1978) and, more recently, by monoclonal antibodies (Ballou et al., 1979) . Preferential tumour uptake of the antibody has been shown, either by measuring tumour and normal-tissue radioactivity after their removal from the host, or by external photoscanning of tumours in situ. However, there have been few recent studies which examine the histological distribution of antibody in tumours in conjunction with its in vivo localization (Ghose et al., 1 980; Koji et al., 1980) . The aim of this study has been to demonstrate by autoradiography (ARG) the tumour-cell specificity of an antitumour monoclonal antibody administered parenterally, and to confirm histologically that the in vivo localization, observed and described recently in an animal model of human tiimours (Moshakis et al., 1981b) , is due to antigenantibody interaction.
MATERIALS AND METHODS
A imonoclonal antibody, LICR LON/HT13.
was raised against cells from the cell line HX39, established from an undifferentiated human malignant teratoma (MTU) xenografted in immune-suppressed mice . In vitro testing by immunofluorescence and cell-binding assay showed strong binding of the antibody to the tumour-cell membrane (> 104 ct/min/105 cells). Between 10 and 15 ,uCi of 1251-labelled antibody (5 [Ci/yug) was injected i.v. into mice carrying the xenografted tumour, together with equal amounts of 1311-labelled normal mouse IgG. The same antibody was used for the in vivo and ARG study of localization in other human germ-cell xenografts and non-germ-cell tumours (Table I) .
At intervals of between 4 and 96 h after injection, the animals were killed, and radioactivity (1251 and 1311) of excised tumours and normal tissues was counted in a dualchannel, w%ell-type scintillation counter (LKB-1280 ultra-gamnma). The preparation of the radioiodinated antibodies, the pathology of the tumours and the in vivo localization experiments, have been described in detail elsewhere (Moshakis et al., 1981b; Monaghan et al., 1981; Raghavan et al., 1981) .
Autoradiographs were made of histological sections of tumours and organs excised during the localization experiments; thus, the degree of antibody uptake of each tumour and organ autoradiographed was known. The tumours and organs were fixed and embedded in paraffin. The loss of radioactivity during fixation and processing was calculated by measuring the radioactivity of representative samples of the fixation and processing reagents. From the 3 fixatives used in pilot experiments (neutral formol saline, Bouin's solution and glutaraldehyde), formol saline was found to cause the least loss of radioactivity. This loss amounted to only 10% with the monoclonal antibody, but was 30-40% with the normal mouse IgG.
Since the sections contained both 1 251 (specific IgG) and 1311 (nonspecific IgG) activity, they were left for 3-4 weeks before being dipped in emulsion (Mahaley et al., 1965) , so that the decay of 1311 and the factors governing the efficiency of grain production (Rogers, 1967) ensured that >95% of the grains were due to the 1251-labelled monoclonal antibody. Dewaxed sections were dipped for 2 sec in photographic emulsion (Ilford K5), maintained at 50°C and at a dilution of 1:1 with distilled water. After the slides had been dried for 30 min, they were placed in light-tight boxes containing silica gel and exposed at 4°C for between 3 days and 5 weeks. Exposed slides were then developed (Kodak D19) and fixed (12-05% Amfix, May & Baker) for 5 min each. Initial experiments enabled us to establish the ideal fixation and developing conditions to give the minimal background activity without appreciable loss of grain formation in the tissues.
Quantitative ARG was undertaken wvith 3 different xenografts, HX39, HX99 and XK1 (Table I) . after their host animal had been injected with 15 tCi of 1251-labelled monoclonal antibody. All tumours were removed from the animals 24h after injection, and were of similar weights (12-1-15-6 mg). Formalin-fixed and paraffin-embedded sections were dipped in emulsion, exposed for 5 weeks, developed, fixed and counterstained with haematoxylin and eosin. Darkfield illumination was used to count grains in 10 random fields in 5 different tumours of each type. Thus, the number of cell-associated grains in a total area of 56 x 103 tZm2 of each section was counted. Background grains were also counted in 10 fields in each section around the tumour at a distance of 1 to 1 fields from the tumour edge.
ARG was also performed with frozen sections of tumours. Animals were injected with either 125L-labelled monoclonal antibody or with 1251-labelled normal IgG. Cryostat-cut sections were placed on slides, fixed in formol saline for 5 min and washed for 5 min in distilled water. They were then dipped in K5 photographic emulsion and processed as described above. In conjunction with ARG of tumours labelled in vivo, ARG was also performed on tumours labelled in vitro. Frozen sections of tumours from animals which had received no radioactivity were fixed in formol saline for 5 min, washed with 0.500 BSA in PBSA and 100 ,ul (105 et/min) of 1251-labelled antibody or 1251-labelled normal IgG was placed over the sections and incubated for 1 h. The slides were washed with 0.500 BSA in PBSA and, after drying, were dipped in K5 photographic emulsion. Exposure in lighttight boxes was for 2-48 h.
In all the experiments, all sets of ARGs contained positive and negative chemography control slides. All slides were examined under bright and dark-field illumination.
RESULTS
The cellular distribution of the monoclonal antibody after in vivo tumour labelling exhibited 2 patterns: (a) an intense subcapsular concentration of grains at the periphery of the tumours over viable tumour cells (Fig. 1) (Fig. 3b) were used for blocking the antigen (Moshakis et al., 1981b) . The cellular distribution of HT 13 in other germ-cell tumour xenografts was the same as in the HX39 tumour, against which the antibody was raised. There was a generalized tendency for the antibody to be segregated in the peripheral, more vascular parts of the tumour and to avoid the central, more necrotic areas. In HX53 (a "mixed" germ-cell tumour containing solid seminoma areas and cystic yolk-sac elements), ARG of in-vivo-labelled tumours demonstrated that HT13 would localize only in the cystic yolk-sac parts of the tumour, and not in the seminoma areas (Fig. 4) . There was no detectable difference in distribution of the antibody between yolk sac and MTU elements when the other germ-cell tumours were examined (HXIII, HX112, HX57), indicating that both elements have the same antigenic determinants for anitibody localization. In the 2 human non-germcell tumours examined by ARG, there was no antibody binding in the breast adenocarcinoma (HX99), but there was strong association of the antibody to viable ttumoLur cells of the renal adenocarcinoma (XK1). This tumour was the only one of 4 non-germ-cell tumours which showed uptake of the antibody in vivo (Moshakis etal., 1981b) . The amount of antibody in the tumours, as found from quantitative ARG, correlated with the various degrees of localization found in the in vivo experiments (Table II) . The absolute visual grain count W1as calculated by subt-racting the background grains from the tumour grains in each section.
When the chemography slides were examined in each set of the ARCs throughout the experiments, neither positive chemographic effects nor significant latent-image fading were found.
I)SCUSSION
Loecalization of i.v. radiolabelled antibodies to tumouirs has been studied in the past either by external radio-imaging or by measurement of tissue radioactivity by means of scintillation counting. Such studies, though important, have certain limitations, however, in that selective homing of the antibody to the tumours can only be expressed as uptake in whole specimens of normal organs and tumours. Demonstration of the binding of the injected antibody to the tumour antigen at cellular level would strengthen any evidence of selective tumour localization obtained from simultaneous in vivo studies, especially when new reagents such as monoclonal antibodies are being examined.
Our finding that the distribution of monoclonal antibody after in vivo tumourlabelling was the same in paraffin-embedded and frozen sections of tumours, confirmed that leaving conventional tumour sections containing both 1251 and 1311 activity for 3-4 weeks before processing produces ARGs with grain formation due to 1251 activity only (i.e. The distribution of the antibody in the other germ-cell tumours was the same as in HX39, indicating that the mechanism of localization was similar, and that all the germ-cell tumours examined to date shared the same antigenic determinant. Although the antibody did not localize in non-germcell tumours such as breast adenocarcinoma, bronchial adenocarcinoma and a squamous-cell carcinoma (Moshakis et al., 1981b) , a high degree of localization was found in a renal adenocarcinoma. The cellular distribution of the injected antibody was the same as in the germ-cell tumours, suggesting that this tumour type can also express the same antigenic determinant.
It is interesting that similar in vrio experiments performed with conventionally raised antibodies to CEA for the localization of human breast-tumour xenografts (Moshakis et al., 1981a) demonstrated that the injected anti-CEA bound mostly to the CEA in the extracellular tumour space, and not to the CEA on the cell membrane (work in progress). However, more work is required to determine whether this is one of the factors responsible for the apparent superiority of monoclonal over conventional antibodies in tumour localization, as seen by us and others (Ballou et al., 1979) .
